Nuvectis Pharma, Inc. financial data

Symbol
NVCT on Nasdaq
Location
1 Bridge Plaza, Suite 275, Fort Lee, NJ
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 277 % -29.2%
Debt-to-equity 56.4 % +64.5%
Return On Equity -161 % -11.1%
Return On Assets -103 % +4.64%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.4M shares +31.6%
Common Stock, Shares, Outstanding 19.5M shares +11.9%
Entity Public Float 50M USD -16.7%
Weighted Average Number of Shares Outstanding, Basic 17.1M shares +10%
Weighted Average Number of Shares Outstanding, Diluted 17.1M shares +10%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 12.9M USD -16%
General and Administrative Expense 6.93M USD -7.82%
Operating Income (Loss) -19.8M USD +13.3%
Net Income (Loss) Attributable to Parent -19M USD +14.6%
Earnings Per Share, Basic -1.11 USD/shares +22.4%
Earnings Per Share, Diluted -1.11 USD/shares +22.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 18.5M USD -3.1%
Other Assets, Current 74K USD +25.4%
Assets, Current 18.6M USD -3.01%
Assets 18.6M USD -3.01%
Accounts Payable, Current 2.5M USD -9.85%
Employee-related Liabilities, Current 5.56M USD +46.3%
Accrued Liabilities, Current 840K USD +102%
Liabilities, Current 8.89M USD +27.3%
Liabilities 8.89M USD +27.3%
Retained Earnings (Accumulated Deficit) -73.2M USD -35%
Stockholders' Equity Attributable to Parent 9.71M USD -20.4%
Liabilities and Equity 18.6M USD -3.01%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.36M USD +8.77%
Net Cash Provided by (Used in) Financing Activities 4.7M USD +1763%
Common Stock, Shares Authorized 60M shares 0%
Common Stock, Shares, Issued 19.5M shares +11.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18.5M USD -3.1%
Deferred Tax Assets, Valuation Allowance 19.5M USD +34.8%
Deferred Tax Assets, Gross 19.5M USD +34.8%
Deferred Tax Assets, Operating Loss Carryforwards 11.6M USD +20.7%
Additional Paid in Capital 83M USD +24.9%
Deferred Tax Assets, Net of Valuation Allowance 0 USD